<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299048</url>
  </required_header>
  <id_info>
    <org_study_id>C3651009</org_study_id>
    <nct_id>NCT04299048</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.</brief_title>
  <official_title>A PHASE 1B, 12-WEEK, OPEN-LABEL STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS FOLLOWING REPEATED SUBCUTANEOUS ADMINISTRATIONS OF PF-06946860 IN PATIENTS WITH CANCER AND CACHEXIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to assess the safety and tolerability of repeated doses of an investigational new drug&#xD;
      in patients with cancer and cachexia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 12-week open-label study will explore how PF-06946860 is tolerated, the effects of the&#xD;
      study drug, the best dose for treatment and how participants with non-small cell lung,&#xD;
      pancreatic or colorectal cancer and cachexia feel after receiving repeated subcutaneous&#xD;
      dosing. During the 12-week treatment period, study drug will be administered subcutaneously&#xD;
      every 3 weeks for a total of 5 doses. There is a 12-week follow-up period following the last&#xD;
      dose of study drug. Additional assessments include:&#xD;
&#xD;
        -  body weight measurements&#xD;
&#xD;
        -  blood pressure and heart rate measurements&#xD;
&#xD;
        -  Lumbar Skeletal Muscle Index (LSMI) by CT scan&#xD;
&#xD;
        -  Blood samples:&#xD;
&#xD;
             -  to evaluate safety,&#xD;
&#xD;
             -  to measure the amount of the study drug in the blood,&#xD;
&#xD;
             -  to evaluate if the study drug causes an immune response,&#xD;
&#xD;
             -  to examine the effects of the study drug on levels of a specific cytokine,&#xD;
&#xD;
             -  and for exploratory samples for bio banking.&#xD;
&#xD;
        -  Measure the impact of the study drug on appetite, nausea, vomiting, fatigue, physical&#xD;
           function, and health-related quality of life with questionnaires.&#xD;
&#xD;
        -  Measure the impact of study drug on physical activity using wearable digital sensors.&#xD;
&#xD;
        -  To evaluate the effect of study drug on ability to complete anti-tumor treatment and&#xD;
           survival in participants with cancer and cachexia.&#xD;
&#xD;
        -  To evaluate tumor size.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety and tolerability of repeated study drug administrations</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence of treatment emergent adverse events (AEs and SAEs), safety laboratory tests, vital signs and standard ECG parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum unbound concentration</measure>
    <time_frame>Weeks 3, 6, 9, 12, and 15</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total trough concentrations (Ctrough)</measure>
    <time_frame>Weeks 3, 6, 9, 12, and 15</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Cachexia</condition>
  <condition>Non-Small-Cell Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>PF-06946860</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06946860</intervention_name>
    <description>subcutaneous injection</description>
    <arm_group_label>PF-06946860</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented histologic or cytologic diagnosis of advanced metastatic NSCLC,&#xD;
             advanced/unresectable pancreatic cancer, or metastatic colorectal cancer.&#xD;
&#xD;
          -  Cachexia, defined by BMI &lt;20 kg/m2 with involuntary weight loss of &gt;2% within 6 months&#xD;
             prior to screening or Involuntary weight loss of &gt;5% within 6 months prior to&#xD;
             screening irrespective of BMI or If medical record documentation is unavailable,&#xD;
             patient's report will suffice to estimate involuntary body weight loss.;&#xD;
&#xD;
          -  Will receive the following for non-small cell lung cancer:&#xD;
&#xD;
               -  a platinum + pemetrexed ± pembrolizumab or&#xD;
&#xD;
               -  a platinum + nab paclitaxel or paclitaxel ± pembrolizumab or&#xD;
&#xD;
               -  pembrolizumab alone&#xD;
&#xD;
          -  Will receive the following for pancreatic cancer:&#xD;
&#xD;
               -  FOLFIRINOX or&#xD;
&#xD;
               -  Nab-Paclitaxel + Gemcitabine&#xD;
&#xD;
               -  Gemcitabine&#xD;
&#xD;
          -  Will receive the following for colorectal cancer:&#xD;
&#xD;
               -  FOLFOX +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or&#xD;
&#xD;
               -  FOLFIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or&#xD;
&#xD;
               -  FOLFOXIRI +/- Biologic (Bevacizumab or Cetuximab/Panitumumab) or&#xD;
&#xD;
               -  Pembrolizumab for MSI-H • Will be entering the study at the first or second cycle&#xD;
                  of their current course of anti-cancer treatment/ therapy.&#xD;
&#xD;
          -  Adequate renal and liver function.&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  All other forms of cancers not specified above unless currently considered cured (&gt;5&#xD;
             years without evidence of recurrence).&#xD;
&#xD;
          -  Planned radiation therapy as part of the primary anti-tumor therapy regimen. However,&#xD;
             localized radiation therapy for symptomatic relief is permitted&#xD;
&#xD;
          -  Cachexia caused by other reasons: Severe COPD requiring use of home O2, heart failure&#xD;
             or AIDS.&#xD;
&#xD;
          -  known symptomatic brain metastases requiring steroids.&#xD;
&#xD;
          -  Active hepatitis B or C virus.&#xD;
&#xD;
          -  Confirmed positive HIV test.&#xD;
&#xD;
          -  Current active reversible causes of decreased food intake.&#xD;
&#xD;
          -  Receiving tube feedings or parenteral nutrition at Screening.&#xD;
&#xD;
          -  Elevated blood pressure that cannot be controlled by medications.&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCL Health Cancer Centers of Colorado - St. Mary's Hospital and Regional Medical Center</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lutheran Medical Center</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <zip>32003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Healthcare Cancer Center</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center Professional Office Building Infusion Pharmacy</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology, Inc.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Oncology Partners of Maryland, PA</name>
      <address>
        <city>Germantown</city>
        <state>Maryland</state>
        <zip>20874</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C3651009</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>March 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cachexia, non-small cell lung cancer, pancreatic cancer</keyword>
  <keyword>colorectal cancer, weight loss, anorexia, muscle loss, fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

